Objectives: Single-nucleotide polymorphism (SNP) arrays have been shown to identify cytogenetic abnormalities in myeloid neoplasms that may be missed by metaphase cytogenetics alone at initial diagnosis. This study examines the utility of serial SNP arrays in follow-up testing of myeloid neoplasms.
Results: Baseline abnormalities were identified by SNP array in 35 (79%) of 44 (79%) compared with 18 (50%) of 36 by metaphase karyotype. In follow-up studies, clonal evolution was found by both SNP array and karyotyping in seven (15.9%), by metaphase karyotyping alone in six (13.6%), and SNP arrays alone in two (4.5%). Overall survival was not significantly different between patients with or without clonal evolution detected by SNP array.
Conclusions: This study, the first systematic examination of serial SNP arrays in myeloid neoplasms, confirms the clinical utility of SNP arrays at initial diagnosis but shows that clonal evolution of the karyotype can be detected by metaphase cytogenetics alone in most patients. Follow-up SNP array testing is not required in routine clinical use in most cases.
Cytogenetic evaluation is an integral part of the diagnosis, classification, and prognostic assessment of myeloid neoplasms, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). [1] [2] [3] [4] Standard G-banded karyotyping has been the cornerstone of cytogenetic evaluation for many years, but results may be limited due to the presence of submicroscopic abnormalities or poor growth that yields inadequate numbers of metaphases for examination. 1, 5, 6 A variety of molecular cytogenetic methods are now available that can enhance the diagnostic yield of metaphase karyotyping. Fluorescence in situ hybridization (FISH) studies can be helpful to detect abnormalities commonly associated with MDS or AML, especially in the setting of poor growth in cytogenetic cultures. [7] [8] [9] [10] [11] [12] FISH, however, is a focused technique that cannot assess
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overall genomic complexity. Array-based approaches, including array comparative genomic hybridization (aCGH), single-nucleotide polymorphism (single-nucleotide polymorphism [SNP] arrays), and combined CGH/SNP arrays offer the ability to detect gains and losses across the genome and, through the use of SNP probes, copy neutral loss of heterozygosity (cnLOH), which will not be detected by FISH or by conventional cytogenetics. 1, 4, [13] [14] [15] [16] [17] Numerous studies have
shown that the combination of array-based methods and metaphase karyotyping provides a higher diagnostic yield in myeloid neoplasms than metaphase cytogenetics alone. 1, 4, 13, 14, 16, [18] [19] [20] While banded karyotyping remains the standard of care for routine clinical practice, recently published guidelines increasingly acknowledge the utility of array-based approaches, at least in some cases such as those with normal karyotype or those with poor growth in cytogenetic cultures. [21] [22] [23] 25 Cytogenetic analysis is also typically performed at the time of follow-up bone marrow biopsy for patients with an established diagnosis of MDS or other myeloid neoplasms. In this setting, cytogenetic data can assist in the diagnosis of persistent disease, identify the presence of clonal evolution that could affect prognosis, and allow for appropriate evaluation of suspected transformations to AML. While numerous studies have now examined the role of array-based karyotyping at initial diagnosis of myeloid neoplasms, 1, 4, 13, 14, 16, [18] [19] [20] there are limited data regarding the clinical utility of array karyotyping in serial samples at the time of follow-up biopsy. In this study, we describe our experience with SNP arrays at baseline and in follow-up samples in a variety of myeloid neoplasms and examine the clinical significance of follow-up findings.
Materials and Methods

Patients
This study was approved by the Cleveland Clinic Institutional Review Board. The Cleveland Clinic pathology archives from June 2012 to April 2014 were reviewed to identify patients with myeloid neoplasms in which more than one sample had been submitted for SNP array testing. Forty-four patients were identified. The available clinical records and results of bone marrow morphology, metaphase karyotyping, and SNP array studies were reviewed.
Metaphase Cytogenetics
Specimens collected in sodium heparin were incubated in culture flasks using Marrowmax medium (Thermo Fisher, New York, NY) for 24-hour unstimulated culture, 48-hour culture containing granulocyte-macrophage colony-stimulating factor (GM-CSF), and 72-hour culture containing phorbol 12-myristate 13-acetate. After the specimens were poured into 15-mL sterile conical tubes, 75 lL colcemid (10 lg/mL) (Life Technologies, Carlsbad, CA) was added to each tube. After 23 minutes, the tubes were harvested on the HANABI P1 automated harvester (Transgenomic, Omaha, NE) using 0.075 mol/L potassium chloride and Carnoy's fixative. The harvester washed the pellet three times in Carnoy's fixative. After the supernatant was aspirated from each tube, the pellet was diluted with Carnoy's fixative until the solution appeared slightly turbid. The harvested tubes were placed inside the Thermotron CDS-5 Chamber (temperature range [22] [23] [24] [25] [26] [27] [28] C, humidity 40%-65%; Thermotron, Holland, MI), and one drop of the cell suspension was dropped onto each labeled slide. A total of five slides per patient were screened under a phase microscope (Model BX41; Olympus, Pittsburgh, PA) for quantity and quality of metaphases. The slides were baked in at 90 C for 30 minutes to remove moisture from the chromosomes. A slide from each culture was run through banding using the SciGene Little Dipper (SciGene, Sunnyvale, CA) according to the Giemsa-banding protocol: pretreatment with 0.02% trypsin for 60 seconds, wash buffer (Nerl Diluent 2/Sheath Fluid; Thermo Fisher Scientific, East Providence, RI) for 15 seconds twice, Wright-Giemsa stain solution for 140 seconds, distilled water for 60 seconds, and spun in an attached centrifuge (690 rpm) for 2 minutes in order. Banding quality in the slides was checked under the light microscope (BX43; Olympus). Good quality of banding was defined as light and dark bands with at least 400 band length and crisp and distinct chromosome edges. The GenAsis Applied Spectral Imaging scanner (Applied Spectral Imaging, Carlsbad, CA) was used to scan the images from Â10 to Â100. Twenty metaphase cells were then analyzed and karyotyped according to the International System for Human Cytogenetic Nomenclature. 24 
SNP Array Karyotyping
SNP microarray analysis of extracted DNA from either the bone marrow or peripheral blood was performed using the Affymetrix CytoScan HD platform (Affymetrix, Santa Clara, CA). Briefly, purified, digested DNA was amplified, fragmented, labeled, and hybridized according to the Affymetrix Cytogenetics Assay Protocol. The samples were scanned on the GeneChip Scanner 3000DX (Affymetrix, Singapore) and data evaluated using the ChAS software (NetAffx; the current version in use is version 32.3 [hg19]; Affymetrix, Santa Clara, CA). The data passed quality control (QC) if the SnpQC (a parameter that estimates difference between distribution of alleles, therefore measuring the genotyping calls that are used to detect LOH) was more than 15, the waviness was less than 0.12, and MAPD (the median of the absolute values of all pairwise differences, which measures the variation of all of the probes used across the genome) was less than 0.25. In the Affymetrix system, data obtained from the patient sample are compared in silico with a proprietary control database. CytoScan HD contains more than 2.6 million markers, approximately 750,000 of which are SNP probes and 1,900,000 of which are nonpolymorphic oligonucleotide probes. The average resolution of the array is one probe/3 Kb in the targeted regions and one probe/ 5 Kb in the backbone.
The data were analyzed for both copy number variations (CNVs) and cnLOH. CNVs of any size that were called by at least 25 markers were evaluated for authenticity and relevance; both terminal and interstitial regions of loss of heterozygosity of 5 Mb or more were evaluated to determine if any known cancer-associated genes were included in the region. Possible constitutional regions of cnLOH were reported only if they included a gene associated with the patient's tumor type; that these regions were possibly constitutional was indicated in the report.
CNVs and regions of cnLOH were classified as pathogenic if the abnormality had been associated with patient outcome in the diagnosed tumor type. A classification of likely pathogenic was made when the abnormality had been reported previously in the disease but not currently associated with a specific outcome. If the abnormality had not been described previously in the tumor type but the size and gene content increased the risk that it could be involved in tumor development or progress, it was classified as of unknown clinical significance. Likely benign CNVs are those involving noncoding and intronic regions or genes with no known association with tumor development. Benign CNVs (ie, those previously observed in healthy individuals and no known association to any disease phenotype) were not reported. The above evaluations were based on the scientific literature and public (Database of Genomic Variants, OMIM, COSMIC) and internal databases.
Statistical Analysis
Survival analysis using the log-rank (Mantel-Cox) test was performed using GraphPad Prism version 6.0 for Windows (GraphPad Software, La Jolla, CA).
Results
Clinicopathologic Characteristics of Patients Studied
Forty-four patients were identified for inclusion in this study Table 1 . Of 139 samples submitted for analysis, six assays from five patients were unsuccessful due to insufficient quantity or quality of DNA obtained, leaving 133 successful arrays (18 peripheral blood, 115 bone marrow). All patients had two or more successful SNP array studies (median, three SNP studies; range, two to eight), with a median time between arrays of 3 months (range, 2 days to 16 months). The complete results of all metaphase karyotyping and SNP array testing are detailed in Supplemental Table 1 (all supplemental materials can be found at American Journal of Clinical Pathology online).
Baseline SNP Analysis vs Metaphase Cytogenetic Results
In baseline SNP analysis, abnormalities were found in 35 (79%) of 44 patients. Concurrent baseline metaphase karyotyping studies were performed in 36 patients, with 18 (50%) showing abnormal findings.
Of the 36 baseline samples with concurrent SNP array and banded karyotyping, 19 (53%) showed at least one pathogenic or likely pathogenic abnormality identified by SNP array that was not identified by metaphase karyotyping. Ten patients (28% of those with concurrent karyotyping and SNP) showed a normal baseline karyotype but were abnormal on SNP array 
Follow-up SNP Analysis vs Metaphase Cytogenetic Results
Results of repeat SNP array compared with baseline status are summarized in Figure 1 . Compared with baseline studies, clonal evolution (ie, gain of additional abnormalities not present at baseline) was identified by both SNP array and metaphase cytogenetics in seven (16%) patients, by SNP array but not metaphase karyotype in two (4%) patients, and by metaphase karyotyping only in six (14%) patients. In seven patients, serial conventional cytogenetics was not performed, but of these, one patient showed clonal evolution on follow-up SNP testing. Twenty-two (50%) patients showed no clonal evolution by either method. The two patients with clonal evolution detected by SNP array but not metaphase karyotyping included one patient with refractory cytopenia with multilineage dysplasia who acquired a 1.5-MB deletion at 19q13.11, including the CEBPA locus, and one patient with a myeloproliferative neoplasm (MPN) consistent with myelofibrosis who acquired a 26-MB loss of chromosome 6p25.3-p22.2 with a concurrent 32-MB gain of chromosome 6p22.2-p11.1.
Clinical Significance of Clonal Evolution
The correlation between clinical course and changes on follow-up SNP arrays is summarized in Figure 2 . During the course of this study, eight patients showed disease progression to AML, progression from low-grade to high-grade MDS, or relapsed disease following a clinical remission. Thirty-three patients showed stable disease and three patients went into clinical remission. Of the eight patients with disease progression or relapse, two showed additional abnormalities on follow-up arrays compared with baseline. Of the 33 patients with clinically stable disease, nine patients showed changes between baseline and follow-up arrays (eight with gains of additional abnormalities and one with loss of baseline abnormalities). Of three patients who went into clinical remission, two had normal findings at baseline and remained normal at remission while one showed abnormal findings at initial diagnosis and a normal result at remission. Median overall survival Figure 3 was 16 months in patients with clonal evolution detected on SNP array vs 
Discussion
In recent years, SNP arrays have emerged as a powerful technique for the detection of chromosomal abnormalities in myeloid neoplasms.
1,4,13,14,16,18-20 SNP arrays not only allow for detection of smaller chromosomal gains and losses that might be missed by metaphase karyotyping but also allow for the detection of cnLOH, which cannot be detected by other techniques. 1, 13, 16, 20 Areas of acquired cnLOH often occur at areas of tumor suppressor genes and suggest duplication of an underlying oncogenic mutation within the affected region. The presence of cnLOH is a recurrent abnormality in MDS and AML and can have prognostic implications. For example, prior studies have demonstrated a similar adverse outcome in patients with either cnLOH or deletions in chromosomes 7, 17p, and 11q. 1, 13, 18, 20 Because high-quality DNA can be readily obtained from peripheral blood or bone marrow, myeloid neoplasms are particularly well suited for study by this method. Moreover, recent studies in MDS have shown that peripheral blood and bone marrow show greater than 95% concordance by SNP arrays, 26 allowing for noninvasive screening or monitoring of patients with known or suspected disease. In the current study, metaphase cytogenetic analysis showed abnormal findings at baseline in 50% of patients compared with 79% yield of baseline SNP array. This result is very similar to previous studies in the literature reporting abnormal findings by SNP array in 75% to 82% of MDS and related diseases such as MDS/MPN and secondary AML. 1, 18, 27 In contrast, only two cases showed abnormal results by metaphase karyotyping that were missed by SNP arrays: one patient with two small unrelated clones with trisomy 8 and trisomy 11 and one patient with an inv (2) . This result is consistent with the known limitations of SNP arrays, which may miss small clones (typically 0%-20% of abnormal metaphases) and balanced structural rearrangements. 4, 13, 14 While it is difficult to completely exclude sampling differences as a source of discrepancies, this appears unlikely given that bone marrow samples were used for both SNP array and metaphase karyotyping in most cases. Overall, these findings emphasize the complementary nature of SNP arrays and metaphase cytogenetics. Cytogenetic data are most often employed at the time of initial diagnosis, where such information is used to establish the presence of a myeloid neoplasm and to assist in classification by World Health Organization (WHO) criteria, 28 as well as provide prognostic information through scoring systems such as the revised International Prognostic Scoring System (IPSS). 29 However, serial analysis of the karyotype over time can also provide important data. The finding of additional abnormalities over time, frequently termed clonal progression or clonal evolution, indicates the presence of karyotypic instability that in some cases can be associated with poor prognosis. [30] [31] [32] Dynamic scoring systems, such as the WHO classificationbased prognostic scoring system, have been proposed to incorporate cytogenetic data as they change over time. 33 There are relatively few data in the literature regarding the utility of serial SNP arrays over time in myeloid neoplasms, largely consisting of description of a small number of patients in whom the additional abnormalities were found to emerge over time, sometimes preceding or accompanying progression to secondary AML. 34, 35 The major purpose of the current study was to examine the clinical significance of serial SNP arrays in patients with myeloid neoplasms. Overall, 32 (73%) of 44 patients showed stable SNP results over time while the remaining 12 (27%) patients showed additional abnormalities in follow-up SNP testing. Interestingly, only two patients in this series showed new abnormalities in serial analysis detected by SNP array alone. These changes represented abnormalities that were too small to be visualized (a 1.5-MB deletion on chromosome 19q) or in a distal portion of a chromosome that would be difficult to detect (a combined deletion/duplication of chromosome 6p) using banded karyotyping. Neither of these abnormalities influenced the classification of the neoplasm, and neither altered the IPSS cytogenetic risk stratification. In contrast, six patients showed development of new abnormalities over time that was detected by metaphase cytogenetics alone. The presence of clonal evolution on SNP array was associated with a possible trend toward shorter overall survival, although this finding was not clinically significant. Because this analysis may be limited by sample size as well as the heterogeneous nature of neoplasms included, treatments applied, and variety of specific abnormalities detected, additional studies will be required to document the clinical significance of individual abnormalities acquired over time in specific neoplasms.
These results have important implications for routine clinical practice. Consistent with prior studies, our data illustrate that the combination of SNP array and metaphase karyotyping markedly improves the detection rate of abnormalities at initial diagnosis. 1, 4, 13, 17, 19 In theory, the addition of a panel of FISH probes could further improve the detection of relatively small clones that might be missed by both methods. However, prior studies comparing the combination of metaphase karyotyping, FISH, and SNP arrays in myeloid disease have shown that such "FISH-only" clones are quite rare. 36, 37 Moreover, the additional abnormalities identified by SNP array testing in this series ( Table 2 and Supplemental Table 1 ) are generally either loci not typically covered by myeloid FISH panels or represent cnLOH that is undetectable by FISH. FISH panels are therefore not an adequate substitute for SNP array analysis. The use of next-generation sequencing panels is rapidly expanding for the detection of recurrent mutations in myeloid neoplasms. [38] [39] [40] Such targeted panels, however, are unable to provide a global overview of copy number status across the genome and are not a substitute for metaphase karyotyping and array-based genotyping. Based on the current series and prior literature, we recommend the use of metaphase karyotyping and SNP array at initial diagnosis. This may be performed concurrently, or more efficiently and cost-effectively, by performing SNP arrays only in cases with normal karyotype or poor growth. For serial follow-up studies, bone marrow chromosome analysis alone appears sufficient given that SNP arrays only rarely detect additional abnormalities that are not also seen by metaphase analysis. Serial SNP arrays may remain valuable, however, if there is a clinical desire to avoid bone marrow biopsy and follow patients noninvasively through peripheral blood analysis alone.
In conclusion, this report represents the first systematic analysis of the clinical utility of SNP array testing in the followup of myeloid neoplasms. In keeping with prior studies, our results demonstrate a role for SNP arrays in the initial diagnostic workup of suspected myeloid neoplasms with a substantial impact on the detection of karyotypic abnormalities. At the time of follow-up studies, however, metaphase karyotyping alone is sufficient for detection of clonal evolution in most cases.
